* Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies ** Based on the treatment policy estimand: estimated efficacy regardless of whether patients stayed on treatment or took other weight loss therapies About CagriSema CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program)
As hydration rises, skin texture looks smoother, softer, and more luminous
Get expert CPT 96372 billing advice today
Cohen, J., Chabbert-Buffet, N
Fight acne, reduce wrinkles, and support tired skin from the inside and out
The interplay between macrophages and angiogenesis in development, tissue injury and regeneration